Paul Mussenden

Paul Mussenden is the current CEO at Cydar Medical. Paul has also previously worked as the Non-executive Deputy Chairman, Chair of Audit & Risk Management Committee at LifeArc Limited from June 2014 to December 2021. Before that, they were with BTG plc from August 2000 to August 2019, where they held the positions of General Counsel, Company Secretary & Head of Strategic Affairs.

Mussenden has broad experience in leading and managing a range of commercial activities. Paul played a key role in building BTG, overseeing its merger and acquisition activities, as well as its funding and subsequent sale to Boston Scientific for $4.2BN. Paul was also responsible for managing the group IP licensing business (~$1B royalty income over 6 years) and a small innovative medical device business unit (low single digit millions p.a. of revenue).

At Cydar Medical, Mussenden is continuing their work in developing and championing innovative therapeutics and diagnostics. Under their leadership, the company is striving to make greater patient impact through its cutting-edge research and development.

Some direct reports include Helen Rae - CFO, Graeme Penney - Chief Scientific Officer & Co-Founder, and Rob Hague - CTO.